Candece L. Gladson
Cleveland Clinic
CancerInternal medicinePathologyFocal adhesionMolecular biologyVitronectinChemistryApoptosisIntegrinImmunologyAutophagyGlioblastomaBevacizumabGliomaAngiogenesisStem cellProgrammed cell deathCancer researchSignal transductionMedicineCell adhesionBiologyCell biology
103Publications
47H-index
8,367Citations
Publications 102
Newest
#1Gaelle Muller-Greven (Cleveland Clinic)H-Index: 4
#2Bianca Maria Marin (Mayo Clinic)H-Index: 1
Last. Candece L. Gladson (Cleveland Clinic)H-Index: 47
view all 8 authors...
Source
#1Nooshin Hashemi-Sadraei (Cleveland Clinic)H-Index: 3
#2Gaelle Muller-Greven (Cleveland Clinic)H-Index: 4
Last. Candece L. Gladson (Cleveland Clinic)H-Index: 47
view all 18 authors...
Background Macroautophagy/autophagy is considered to play key roles in tumor cell evasion of therapy and establishment of metastases in breast cancer. High expression of LC3, a residual autophagy marker, in primary breast tumors has been associated with metastatic disease and poor outcome. FIP200/Atg17, a multi-functional pro-survival molecule required for autophagy, has been implicated in brain metastases in experimental models. However, expression of these proteins has not been examined in bra...
Source
#1Gaelle Muller-Greven (KSU: Kent State University)H-Index: 4
#2Cathleen R. Carlin (Case Western Reserve University)H-Index: 26
Last. Candece L. Gladson (Cleveland Clinic)H-Index: 47
view all 15 authors...
Purpose: Bevacizumab, a humanized monoclonal antibody to VEGF, is used routinely in the treatment of patients with recurrent glioblastoma (GBM). However, very little is known regarding the effects of bevacizumab on the cells in the perivascular space in tumors. Experimental Design: Established orthotopic xenograft and syngeneic models of GBM were used to determine entry of monoclonal anti-VEGF-A into, and uptake by cells in, the perivascular space. Based on the results, we examined CD133+ cells ...
Source
#1Manmeet S. Ahluwalia (Cleveland Clinic)H-Index: 42
#2Stephanie Bou-Anak (Cleveland Clinic)H-Index: 2
Last. Candece L. Gladson (Cleveland Clinic)H-Index: 47
view all 19 authors...
The circulating levels of soluble tumor necrosis factor receptor-1 (sTNF-R1) and sTNF-R2 are altered in numerous diseases, including several types of cancer. Correlations with the risk of progression in some cancers, as well as systemic manifestations of the disease and therapeutic side-effects, have been described. However, there is very little information on the levels of these soluble receptors in glioblastoma (GBM). Here, we report on an exploratory retrospective study of the levels of sTNF-...
Source
#1Candece L. Gladson (UAB: University of Alabama at Birmingham)H-Index: 47
#2David A. Cheresh (Scripps Research Institute)H-Index: 137
Source
#4Xinning Wang (Cleveland Clinic)H-Index: 14
Low serum selenium or selenoprotein P (SePP) levels have been repetitively observed in severe sepsis. The role of SePP in sepsis is incompletely characterized. To test the hypothesis that lipopolysaccharide (LPS) interacts with SePP, we investigated the interaction between LPS and the histidine-rich (His-rich) regions of SePP. We demonstrate that both purified SePP and synthetic peptides corresponding to the His-rich motifs neutralized LPS. In addition, we used a hepatocyte model to study the fa...
Source
#1Gaelle Muller-Greven (Cleveland Clinic)H-Index: 4
#2Cathleen R. Carlin (Case Western Reserve University)H-Index: 26
Last. Candece L. Gladson (Cleveland Clinic)H-Index: 47
view all 9 authors...
Most patients with recurrent glioblastoma (GBM) are treated with bevacizumab, a humanized monoclonal antibody (mAb) that binds VEGF-A and inhibits its binding to VEGFR. Approximately 30% of GBM patients are non-responsive to bevacizumab and the underlying mechanism for the lack of response is not known. It has been assumed that bevacizumab solely targets circulating VEGF-A in blood. We hypothesized that bevacizumab and human IgGs in general gain access to the perivascular niche that contains can...
Source
#1Monica E. Burgett (Cleveland Clinic)H-Index: 4
#2Justin D. Lathia (Cleveland Clinic)H-Index: 64
Last. Candece L. GladsonH-Index: 47
view all 15 authors...
// Monica E. Burgett 1, 6 , Justin D. Lathia 2 , Patrick Roth 7 , Amy S. Nowacki 4 , Deni S. Galileo 10 , Elena Pugacheva 8 , Ping Huang 1 , Amit Vasanji 9 , Meizhang Li 2 , Tatiana Byzova 5 , Tom Mikkelsen 11 , Shideng Bao 3 , Jeremy N. Rich 3 , Michael Weller 7 , Candece L. Gladson 1 1 Department of Cancer Biology, Cleveland Clinic, Cleveland, OH, USA 2 Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH, USA 3 Department of Stem Cell Biology and Regenerative Medicin...
Source
#1Daniel J. Klionsky (UM: University of Michigan)H-Index: 140
#2Kotb Abdelmohsen (NIH: National Institutes of Health)H-Index: 67
Last. Susu M. Zughaier (Emory University)H-Index: 29
view all 2461 authors...
In 2008 we published the first set of guidelines for standardizing research in autophagy. Since then, research on this topic has continued to accelerate, and many new scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Accordingly, it is important to update these guidelines for monitoring autophagy in different organisms. Various reviews have described the range of assays that have been used for this purpose. Nevertheless, there continues...
Source
#1Daniel J. Klionsky (UM: University of Michigan)H-Index: 140
#2Kotb Abdelmohsen (NIH: National Institutes of Health)H-Index: 67
Last. Khosrow Adeli (U of T: University of Toronto)H-Index: 80
view all 2461 authors...
Author(s): Klionsky, DJ; Abdelmohsen, K; Abe, A; Abedin, MJ; Abeliovich, H; Arozena, AA; Adachi, H; Adams, CM; Adams, PD; Adeli, K; Adhihetty, PJ; Adler, SG; Agam, G; Agarwal, R; Aghi, MK; Agnello, M; Agostinis, P; Aguilar, PV; Aguirre-Ghiso, J; Airoldi, EM; Ait-Si-Ali, S; Akematsu, T; Akporiaye, ET; Al-Rubeai, M; Albaiceta, GM; Albanese, C; Albani, D; Albert, ML; Aldudo, J; Algul, H; Alirezaei, M; Alloza, I; Almasan, A; Almonte-Beceril, M; Alnemri, ES; Alonso, C; Altan-Bonnet, N; Altieri, DC; A...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.